Long‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation
Journal of the American Heart Association · 21.04.2026 · 15 (8)
DOI: 10.1161/jaha.125.045788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.04.2026. Verfasst von Ayse-Gül Öztürk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Solna Karolinska Institutet Stockholm Sweden. Hauptthemen laut MEDLINE: Fontan Procedure, Fibrinolytic Agents, Univentricular Heart, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
An effective antithrombotic strategy for patients with univentricular heart is required. We determined the prevalence of antithrombotic treatment and survival in patients with Fontan circulation, with secondary outcomes mortality, cardiovascular disease, acute myocardial infarction, and ischemic stroke.
Methods
We retrospectively included patients with univentricular heart born in Sweden between January 1, 1970, and December 31, 2017. Data from the National Patient Register, the Cause of Death Register, and the Prescribed Drug Register were used. Patients who underwent total cavopulmonary connection surgery, resulting in Fontan circulation, were included and divided into groups based on treatment: anticoagulation, antiplatelets, and no antithrombotic therapy.
Results
In total, 864 patients (median [interquartile range] 14.4 [3.9–24.9] years follow‐up) were included, 511 of whom (59%) were men. Thirty‐six percent received no antithrombotic treatment, and the mortality rate during the follow‐up was 58%. Among the patients treated with antithrombotic treatment, 75% received antiplatelets, with a 4% mortality rate. The mortality incidence rate was 2.40 (95% CI, 1.49–3.67) for antithrombotic treatment and 49.42 (95% CI, 42.50–57.15) without. The hazard ratio for mortality was 22.32 (95% CI, 14.04–35.48) without antithrombotic treatment. The incidence rate of ischemic stroke was 2.45 (95% CI, 1.52–3.75) with antithrombotic treatment and 2.47 (95% CI, 1.13–4.68) without. The incidence rate of acute myocardial infarction was 0.69 (95% CI, 0.25–1.50) with antithrombotic treatment and 2.76 (95% CI, 1.32–5.07) without treatment.
Conclusions
Treatment with antiplatelets was associated with lower mortality compared with no antithrombotic treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine Solna Karolinska Institutet Stockholm Sweden.
- Department of Cardiology Karolinska University Hospital Stockholm Sweden.
- Institute of Medicine-Sahlgrenska Academy University of Gothenburg Gothenburg Sweden.
- Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden.
- Department of Medicine, Geriatrics and Emergency Medicine Sahlgrenska University Hospital Gothenburg Sweden.
- Adult Congenital Heart Unit, Department of Medicine Sahlgrenska University Hospital Gothenburg Sweden.
ORCID-Profile: Ayse-Gül Öztürk, Mikael Dellborg, Anna Damlin, Kok Wai Giang, Zacharias Mandalenakis, Peder Sorensson
Zitieren
APA
Öztürk, A. G., Dellborg, M., Damlin, A., Giang, K. W., Mandalenakis, Z., & Sorensson, P. (2026). Long‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation. Journal of the American Heart Association, 15(8). https://doi.org/10.1161/jaha.125.045788
Vancouver
Öztürk AG, Dellborg M, Damlin A, Giang KW, Mandalenakis Z, Sorensson P. Long‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation. Journal of the American Heart Association. 2026;15(8). doi:10.1161/jaha.125.045788
BibTeX
@article{ztrk2026,
author = {Öztürk, Ayse-Gül and Dellborg, Mikael and Damlin, Anna and Giang, Kok Wai and Mandalenakis, Zacharias and Sorensson, Peder},
title = {Long‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {8},
doi = {10.1161/jaha.125.045788}
}
EUVIMED